Literature DB >> 20806987

The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications.

Roger S McIntyre1, Ka Young Park, Candy W Y Law, Farah Sultan, Amanda Adams, Maria Teresa Lourenco, Aaron K S Lo, Joanna K Soczynska, Hanna Woldeyohannes, Mohammad Alsuwaidan, Jinju Yoon, Sidney H Kennedy.   

Abstract

Major depressive disorder is a prevalent recurrent medical syndrome associated with inter-episodic dysfunction. The metabolic syndrome is comprised of several established risk factors for cardiovascular disease (i.e. abdominal obesity, dyslipidaemia, dysglycaemia and hypertension). The criterion items of the metabolic syndrome collectively represent a multi-dimensional risk factor for cardiovascular disease and type 2 diabetes mellitus. Extant evidence indicates that both major depressive disorder and the metabolic syndrome, albeit distinct, often co-occur and are possibly subserved by overlapping pathophysiology and causative mechanisms. Conventional antidepressants exert variable effects on constituent elements of the metabolic syndrome, inviting the need for careful consideration prior to treatment selection and sequencing. Initiating and maintaining antidepressant therapy should include routine surveillance for clinical and/or biochemical evidence suggestive of the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20806987     DOI: 10.2165/11533280-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  172 in total

1.  Changes in weight during a 1-year trial of fluoxetine.

Authors:  D Michelson; J D Amsterdam; F M Quitkin; F W Reimherr; J F Rosenbaum; J Zajecka; K L Sundell; Y Kim; C M Beasley
Journal:  Am J Psychiatry       Date:  1999-08       Impact factor: 18.112

2.  Diabetes mellitus in schizophrenic patients.

Authors:  S Mukherjee; P Decina; V Bocola; F Saraceni; P L Scapicchio
Journal:  Compr Psychiatry       Date:  1996 Jan-Feb       Impact factor: 3.735

Review 3.  Monoamine oxidase inhibitors and weight gain.

Authors:  T G Cantú; J S Korek
Journal:  Drug Intell Clin Pharm       Date:  1988-10

4.  Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study.

Authors:  T Ljung; A C Ahlberg; G Holm; P Friberg; B Andersson; E Eriksson; P Björntorp
Journal:  J Intern Med       Date:  2001-09       Impact factor: 8.989

5.  Metabolic changes in elderly patients with major depression: evidence for increased accumulation of visceral fat at follow-up.

Authors:  Bettina Weber-Hamann; Marc Werner; Frank Hentschel; Nils Bindeballe; Florian Lederbogen; Michael Deuschle; Isabella Heuser
Journal:  Psychoneuroendocrinology       Date:  2005-10-06       Impact factor: 4.905

6.  Associations between waist circumference and depressive disorders.

Authors:  Isabel Hach; Uwe E Ruhl; Jens Klotsche; Michael Klose; Frank Jacobi
Journal:  J Affect Disord       Date:  2006-02-28       Impact factor: 4.839

7.  Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients.

Authors:  Leyla Gülseren; Seref Gülseren; Zeliha Hekimsoy; Levent Mete
Journal:  Arch Med Res       Date:  2005 Mar-Apr       Impact factor: 2.235

8.  Imipramine and weight gain during the treatment of recurrent depression.

Authors:  E Frank; D J Kupfer; C M Bulik; J A Levenson
Journal:  J Affect Disord       Date:  1990-11       Impact factor: 4.839

9.  A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study.

Authors:  D Bakish; J Bradwejn; N Nair; J McClure; R Remick; L Bulger
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.

Authors:  Patrice Boyer; Stuart Montgomery; Ulla Lepola; Jean-Michel Germain; Claudine Brisard; Rita Ganguly; Sudharshan K Padmanabhan; Karen A Tourian
Journal:  Int Clin Psychopharmacol       Date:  2008-09       Impact factor: 1.659

View more
  23 in total

Review 1.  Functional biomarkers of depression: diagnosis, treatment, and pathophysiology.

Authors:  Heath D Schmidt; Richard C Shelton; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

2.  Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population.

Authors:  Michael J Bly; Stephan F Taylor; Gregory Dalack; Rodica Pop-Busui; Kyle J Burghardt; Simon J Evans; Melvin I McInnis; Tyler B Grove; Robert D Brook; Sebastian K Zöllner; Vicki L Ellingrod
Journal:  Bipolar Disord       Date:  2013-12-13       Impact factor: 6.744

3.  Socioeconomic Disparities and Metabolic Risk in Veterans with Serious Mental Illness.

Authors:  Stanley N Caroff; Shirley H Leong; Daisy Ng-Mak; E Cabrina Campbell; Rosalind M Berkowitz; Krithika Rajagopalan; Chien-Chia Chuang; Antony Loebel
Journal:  Community Ment Health J       Date:  2017-12-28

4.  Depressive symptoms are associated with worsened severity of the metabolic syndrome in African American women independent of lifestyle factors: A consideration of mechanistic links from the Jackson heart study.

Authors:  Matthew J Gurka; Abhishek Vishnu; Olivia I Okereke; Solomon Musani; Mario Sims; Mark D DeBoer
Journal:  Psychoneuroendocrinology       Date:  2016-03-03       Impact factor: 4.905

Review 5.  Metabolic syndrome as a risk factor for neurological disorders.

Authors:  Akhlaq A Farooqui; Tahira Farooqui; Francesco Panza; Vincenza Frisardi
Journal:  Cell Mol Life Sci       Date:  2011-10-15       Impact factor: 9.261

6.  Clinical use of antidepressant therapy and associated cardiovascular risk.

Authors:  W Stephen Waring
Journal:  Drug Healthc Patient Saf       Date:  2012-08-17

Review 7.  Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies.

Authors:  An Pan; Nana Keum; Olivia I Okereke; Qi Sun; Mika Kivimaki; Richard R Rubin; Frank B Hu
Journal:  Diabetes Care       Date:  2012-05       Impact factor: 19.112

8.  Agomelatine as monotherapy for major depression: an outpatient, open-label study.

Authors:  Jan Pecenak; Vladimir Novotny
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-22       Impact factor: 2.570

9.  Four-year analysis of cardiovascular disease risk factors, depression symptoms, and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes.

Authors:  Richard R Rubin; Mark Peyrot; Sarah A Gaussoin; Mark A Espeland; Don Williamson; Lucy F Faulconbridge; Thomas A Wadden; Linda Ewing; Monika Safford; Gina Evans-Hudnall; Rena R Wing; William C Knowler
Journal:  Diabetes Care       Date:  2013-01-28       Impact factor: 19.112

10.  Metabolic Syndrome in Drug-naïve Patients with Depressive Disorders.

Authors:  Sandeep Grover; Naresh Nebhinani; Subho Chakrabarti; Ajit Avasthi; Parmanand Kulhara
Journal:  Indian J Psychol Med       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.